3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Prostatic Neoplasms
22
Breast Neoplasms
3
Triple Negative Breast Neoplasms
2
Prostate Adenocarcinoma
2
Neoplasm Metastasis
2
Stage I Prostate Adenocarcinoma AJCC v7
1
Salivary Gland Neoplasms
1
Primary Dysautonomias
1
Paget Disease, Extramammary
1
PSA Level Greater Than Two
1
Non-Muscle Invasive Bladder Urothelial Carcinoma
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Kidney Diseases
1
Hypertension
1
Glioma
1
Glioblastoma
1
Carcinoma, Renal Cell
1
Bulbo-Spinal Atrophy, X-Linked
1
Interventions
Gemcitabine
16
Mitomycin
10
Docetaxel
6
BCG Vaccine
6
erdafitinib
5
durvalumab
4
dodecyl maltoside
4
Cystoscopy
4
ALT-803
4
Radiotherapy
2
5-aminolevulinic acid hexyl ester
2
viscum album peptide
1
tremelimumab
1
toripalimab
1
pirarubicin
1
pemigatinib
1
monalizumab
1
hydroxycamptothecinum
1
enfortumab vedotin
1
chondroitin sulfate, sodium hyaluronate drug combination
1
bicalutamide
1
Watchful Waiting
1
Urine Specimen Collection
1
Transurethral Resection of Bladder
1
Surveys and Questionnaires
1
Patient Discharge
1
Paclitaxel
1
Nonsteroidal Anti-Androgens
1
Mitozytrex
1
Maintenance
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Non-Muscle Invasive Bladder Neoplasms
×
bicalutamide
×
1 year
×
Clear all
NCT05327647
2025-12-18
BicaBCa
CHU de Quebec-Universite Laval
Phase 2
Recruiting
160 enrolled